Skip to main content
Medical information Clinical review pending

Cytogenetics

Immunohistochemistry Digital Breast Cancer Panel 3 Test

An advanced diagnostic test using immunohistochemistry to analyze breast tumor tissue for key biomarkers (ER, PR, HER-2) that guide personalized cancer treatment decisions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Tumor tissue sample. This can be submitted as a 10% Formal-saline or Formalin fixed paraffin embedded block.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. Ensure the tumor tissue sample is properly collected and preserved. Provide a copy of the Histopathology report, indicating the site of biopsy and relevant clinical history.
Test priceKSh 14,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Immunohistochemistry Digital Breast Cancer Panel 3 Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of breast cancer.
  • ✓Characterization of known breast cancer.
  • ✓Guiding treatment decisions for breast cancer.
  • ✓Patients presenting with breast lumps or changes.
  • ✓Patients with a family history of breast cancer.
02

In plain language

What this test helps you understand

This test helps determine the presence of specific biomarkers (ER, PR, HER-2) in breast tumor tissue. This information is crucial for classifying the type of breast cancer and guiding personalized treatment decisions, such as hormone therapy or targeted therapy.
The Immunohistochemistry Digital Breast Cancer Panel 3 Test is an advanced diagnostic tool used to assess breast cancer by analyzing tumor tissue samples. This test plays a crucial role in determining the presence of specific biomarkers that guide treatment decisions and patient management. With the increasing incidence of breast cancer, timely and accurate diagnosis is essential for effective treatment.

This panel detects several key components in tumor tissue, including Estrogen Receptor (ER), Progesterone Receptor (PR), and HER-2 Status. It also includes photomicrograph analysis and pathologist review for malignant cells.

Taking this test offers numerous advantages, including accurate identification of hormone receptors that influence treatment options, guidance for oncologists in selecting personalized treatment plans, and timely diagnosis leading to better patient outcomes.

Results from the test will be reviewed by our expert pathologists. A detailed report will outline the presence of specific markers, aiding in the understanding of the type and aggressiveness of cancer. This information is vital for determining the most effective treatment strategy.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Ensure the tumor tissue sample is properly collected and preserved. Provide a copy of the Histopathology report, indicating the site of biopsy and relevant clinical history.
SampleTumor tissue sample. This can be submitted as a 10% Formal-saline or Formalin fixed paraffin embedded block.
MethodologyImmunohistochemistry (IHC) is used to detect the presence and location of specific proteins (biomarkers) within the tumor tissue sample. Pathologists review the stained tissue under a microscope.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
The accuracy of the test depends on the quality and quantity of the submitted tissue sample. Results may be affected by inadequate tissue preservation or processing. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test detects key biomarkers in breast cancer tissue, including Estrogen Receptor (ER), Progesterone Receptor (PR), and HER-2 status, which help guide treatment.
A tissue sample from the breast tumor is required. This is typically obtained during a biopsy or surgery and submitted as a formalin-fixed paraffin block.
Confirm with the laboratory before booking.
Our expert pathologists review the test results and provide a detailed report.
The test itself is performed on a tissue sample, not directly on the patient, so it is not painful. The initial biopsy procedure may cause discomfort.
We have branches in Nairobi, Mombasa, and Kisumu. We also offer a home sample collection service. Please contact us to arrange.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp